Search research articles
Contact Us
Filters
Showing results (1-10 of 340) with videos related to
Page
of 34
Sort By:
European Urology
|
March 14, 2009
Editorial comment on: A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer
Henk G van der Poel
European Urology
|
April 8, 2009
Chemical castration and survival in low-risk prostate cancer
Henk G van der Poel
European Urology
|
August 9, 2007
Editorial comment on: Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer
Henk G van der Poel
European Urology
|
April 24, 2007
Editorial comment on: marked gene transcript level alterations occur early during radical prostatectomy
Henk G van der Poel
European Urology
|
July 1, 2008
Editorial comment on: Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients
Henk G van der Poel
European Urology
|
May 27, 2008
Editorial comment on: Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial CEFUB)
Henk G van der Poel
European Urology
|
March 17, 2020
Re: Apalutamide and Overall Survival in Non-metastatic Castration-resistant Prostate Cancer
Henk G van der Poel
European Urology
|
October 14, 2009
Words of wisdom. Re: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Tran C, Ouk S, Clegg NJ, et al
Henk G van der Poel
BJU International
|
September 27, 2014
Extent of lymph node metastases
Henk G van der Poel
European Urology
|
April 22, 2006
Foreseeing cancer metastases
Henk G van der Poel
Page
of 34
Search research articles
Search
Showing results (1-10 of 340) with videos related to
Sort By:
Page
of 34
European Urology
|
March 14, 2009
Editorial comment on: A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer
Henk G van der Poel
European Urology
|
April 8, 2009
Chemical castration and survival in low-risk prostate cancer
Henk G van der Poel
European Urology
|
August 9, 2007
Editorial comment on: Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer
Henk G van der Poel
European Urology
|
April 24, 2007
Editorial comment on: marked gene transcript level alterations occur early during radical prostatectomy
Henk G van der Poel
European Urology
|
July 1, 2008
Editorial comment on: Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients
Henk G van der Poel
European Urology
|
May 27, 2008
Editorial comment on: Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial CEFUB)
Henk G van der Poel
European Urology
|
March 17, 2020
Re: Apalutamide and Overall Survival in Non-metastatic Castration-resistant Prostate Cancer
Henk G van der Poel
European Urology
|
October 14, 2009
Words of wisdom. Re: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Tran C, Ouk S, Clegg NJ, et al
Henk G van der Poel
BJU International
|
September 27, 2014
Extent of lymph node metastases
Henk G van der Poel
European Urology
|
April 22, 2006
Foreseeing cancer metastases
Henk G van der Poel
Page
of 34